Table 3

Data holdings approved for the research programme

Data set First available date in Australia	Description	Metastatic				Early-stage	Neoadjuvant
		Trastuzumab	Lapatinib	T-DM1	Pertuzumab	Trastuzumab	Trastuzumab
		2001	2008	2015	2015	2006	2012
Patient demographics	Year of birth; sex; mm/yy of death; state of residence and postcode of residence mapped to SLA*	X	X	X	X	X	X
Patient weight	Patient weight (kg) at the time of Herceptin Programme enrolment	X	X
Treatment qualification	Patient HER2 overexpression levels and the test used to ascertain levels (IHC or ISH). Initial intended treatment—monotherapy or concomitant treatment with taxanes	X	X
PBS	All prescribed medicines reimbursed by the PBS. Variables include medicine name and strength, date of prescribing, date of supply, quantity supplied/pack size, the number of repeats allowed with the prescription, patient copayment contribution and the cost to government	X	X	X	X	X	X
Trastuzumab supply	Dates and phial of trastuzumab dispensed to Herceptin Programme participants	X
MBS	All medical and allied health services. Variables includes the type of service rendered—from outpatient doctor visits to surgeries—the cost and benefit paid for the service, and the date of service	X	X

*SLA classifies geographic areas of Australia by socioeconomic profile and remoteness.64 ,65
IHC, immunohistochemistry; ISH, in situ hybridisation; MBS, Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Scheme; SLA, statistical local area.